- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07941947
Atrial Coronary Circulation in STEMI Patients With Newly Diagnosed Atrial Fibrillation (ACC-AF-STEMI)
Atrial Coronary Circulation in STEMI Patients With Newly Diagnosed Atrial Fibrillation (ACC-AF-STEMI)
This multicenter, prospective, observational, comparative cohort study will investigate the association between atrial coronary artery involvement and newly diagnosed atrial fibrillation (AF) in patients with ST-segment elevation myocardial infarction (STEMI).
Patients with acute STEMI undergoing coronary angiography will be assigned to two observational cohorts according to the development of AF during the first 24 hours of hospitalization: patients with a first-ever episode of AF and patients without AF, with the latter group matched by age and sex. Coronary angiograms will be assessed for thrombosis or stenosis of the arteries supplying the atria and for their relationship to the infarct-related artery.
The primary endpoint is the incidence of atrial coronary artery involvement in patients with newly diagnosed AF during acute STEMI. Secondary endpoints include all-cause and cardiovascular mortality, acute heart failure, thromboembolic complications, major bleeding, duration of hospitalization and intensive care stay, AF recurrence, cardioversion, and prescription of direct oral anticoagulants during hospitalization.
The study plans to enroll 400 participants, with 200 patients in each cohort. The study is non-interventional, and all diagnostic and therapeutic procedures will be performed according to standard clinical care. The follow-up will include the index hospitalization and a 30-day telephone assessment.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Atrial fibrillation (AF) is a common complication of acute ST-segment elevation myocardial infarction (STEMI) and is associated with adverse clinical outcomes, including acute heart failure, thromboembolic complications, prolonged hospitalization, and increased mortality. Despite advances in reperfusion therapy and contemporary STEMI management, the mechanisms underlying the development of newly diagnosed AF during acute STEMI remain incompletely understood. In particular, the potential role of the coronary arteries supplying the atrial myocardium has not been sufficiently characterized.
The ACC-AF-STEMI study is a multicenter, prospective, observational, comparative cohort study designed to investigate the association between atrial coronary artery involvement and the development of de novo AF during acute STEMI. The scientific hypothesis is that thrombosis or atherosclerotic lesions of the arteries supplying the atria, particularly when these vessels are related to the infarct-related artery, may contribute to the development of AF during the acute phase of STEMI.
Patients with a verified diagnosis of STEMI who undergo coronary angiography will be prospectively enrolled. Participants will be divided into two observational cohorts according to the development of AF during the first 24 hours of hospitalization. The main cohort will include patients with a first-ever episode of AF occurring during acute STEMI. The comparison cohort will include patients with STEMI who do not develop AF during hospitalization and will be matched by age and sex.
The key study procedure is systematic assessment of coronary angiograms. In addition to evaluation of the infarct-related artery and multivessel coronary disease, the angiographic analysis will assess thrombosis or stenosis of the arteries supplying the atria, including the right ostial/conus-related atrial branches (ROCS), atrioventricular nodal artery (AVNA), right inferior atrial artery (RIAA), and left inferior atrial artery (LIAA), as specified in the protocol. Their origin and relationship to the infarct-related artery, as well as TIMI flow before and after percutaneous coronary intervention (PCI), will be documented. Angiographic assessment will be performed by a specialized angiography committee blinded to the patient's AF status in order to minimize assessment bias.
AF will be identified using continuous electrocardiogram (ECG) monitoring during the initial intensive care unit (ICU) period, daily 12-lead ECGs, and recording of symptomatic episodes. Echocardiographic assessment will include left atrial volume index, mitral regurgitation, left ventricular ejection fraction according to the Simpson method, pulmonary artery systolic pressure, and E/E'. Clinical, laboratory, ECG, echocardiographic, angiographic, procedural, and treatment data will be prospectively recorded in an electronic case report form.
The primary endpoint is the incidence of atrial coronary artery involvement in patients with newly diagnosed AF during acute STEMI. Secondary endpoints include all-cause mortality, cardiovascular mortality, development of acute heart failure (Killip class ≥ II), thromboembolic complications including stroke and pulmonary embolism, and major bleeding defined as Bleeding Academic Research Consortium (BARC) grade ≥3. Additional outcomes include duration of hospitalization and ICU stay, type and number of cardioversions, recurrence of AF during hospitalization, failure to restore sinus rhythm, and prescription of direct oral anticoagulants during hospitalization.
The planned target sample size is 400 patients, with 200 participants in each cohort. The protocol's sample-size calculation was based on an expected difference in atrial coronary artery involvement between patients with STEMI and newly diagnosed AF and those without AF. The larger target sample is intended to support multivariable analysis and account for potential technical limitations in angiographic assessment and the relatively low prevalence of AF among patients with STEMI.
Patient recruitment is planned over 12 months. Each participant will be followed during the index hospitalization, with assessment of acute clinical outcomes, and will additionally undergo a 30-day telephone follow-up. The study is planned as a multicenter and multinational investigation, with the Samara Regional Clinical Cardiology Dispensary named after V.P. Polyakov serving as the initiating center and additional PCI-capable hospitals participating through the STEMI network.
The study is non-interventional. Coronary angiography, PCI, pharmacological treatment, cardioversion, anticoagulant therapy, and other diagnostic or therapeutic procedures will be performed solely according to clinical indications and applicable standards of care. Participation in the study does not determine or modify the treatment received by patients.
Safety information, including serious adverse events occurring from coronary angiography through hospital discharge and during the 30-day follow-up period, will be recorded. Events of particular interest include procedure-related death, stroke, major bleeding, acute kidney injury, coronary artery perforation or aortic dissection, emergency сoronary artery bypass grafting (CABG), thromboembolic complications, severe bradycardia or sinus arrest requiring temporary pacing, and cardiac tamponade.
The study is intended to improve understanding of the relationship between atrial coronary artery involvement and newly diagnosed AF during acute STEMI and to characterize the clinical and angiographic features associated with this complication.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Dmitry V. Duplyakov
- Puhelinnumero: +79277297273
- Sähköposti: duplyakov@yahoo.com
Tutki yhteystietojen varmuuskopiointi
- Nimi: Larisa Shekhovtsova
- Puhelinnumero: +79524299333
- Sähköposti: shekhovtsova_l@mail.ru
Opiskelupaikat
-
-
-
Samara, Venäjä, 443070
- Samara Regional Cardiology Dispansery
-
Ottaa yhteyttä:
- Dmitry V. Duplyakov, MD, PhD
- Puhelinnumero: +79277297273
- Sähköposti: duplyakov@yahoo.com
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Adults with acute ST-elevation myocardial infarction (STEMI) admitted within 24 hours of symptom onset and undergoing coronary angiography with or without percutaneous coronary intervention (PCI). The study includes patients with no previous history of atrial fibrillation who either develop first-ever atrial fibrillation within the first 24 hours of hospitalization or remain free of atrial fibrillation during hospitalization. The comparison cohort is matched by age and sex.
Kuvaus
Inclusion Criteria:
- Main cohort - STEMI patients with newly diagnosed atrial fibrillation: Age 18-75 years. ST-elevation myocardial infarction (STEMI) with symptom onset within 24 hours before enrollment.
No history of atrial fibrillation before the index STEMI. First-ever episode of atrial fibrillation documented within the first 24 hours of hospitalization.
Coronary angiography with or without percutaneous coronary intervention (PCI). Written informed consent.
- Control cohort - STEMI patients without atrial fibrillation:
Age ≥18 years. STEMI with symptom onset within 24 hours before enrollment. No history of atrial fibrillation before the index STEMI. No first-ever episode of atrial fibrillation during hospitalization. Coronary angiography with or without PCI. Written informed consent.
Exclusion Criteria:
- Known history of AF prior to STEMI.
- Time from onset of STEMI symptoms > 24 hours.
- Chronic Obstructive Pulmonary Disease stage ≥2.
- History of Myocardial Infarction.
- History of previous PCI or CABG.
- History of Valve Surgery.
- Mitral or Tricuspid Valve insufficiency grade ≥ 2.
- Hemodynamically significant Mitral Stenosis (<1.5 cm2).
- Permanent pacemaker.
- Malignancy in the active treatment phase or terminal cancer.
- Severe comorbidities (e.g., end-stage CKD, cirrhosis) with a life expectancy of less than 1 year.
- Known thyrotoxicosis.
- Non-invasive treatment strategy.
- Patient's refusal to participate in the study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: PROSPECTIVE
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
STEMI With Newly Diagnosed Atrial Fibrillation
Patients with STEMI who develop a first-ever episode of atrial fibrillation during the first 24 hours of hospitalization. Patients have no history of atrial fibrillation before STEMI and undergo coronary angiography with or without subsequent PCI. |
Presence of thrombosis and/or stenosis of atrial coronary artery branches (ROCS, AVNA, RIAA, and LIAA), including their relationship to the infarct-related artery and TIMI flow, assessed by coronary angiography. This exposure is not assigned by the study investigators and is observed during standard-of-care coronary angiography. |
|
STEMI Without Atrial Fibrillation
Patients with STEMI who do not develop atrial fibrillation during hospitalization. Patients have no history of atrial fibrillation before STEMI and undergo coronary angiography with or without subsequent PCI. The comparison cohort is matched by age and sex. |
Presence of thrombosis and/or stenosis of atrial coronary artery branches (ROCS, AVNA, RIAA, and LIAA), including their relationship to the infarct-related artery and TIMI flow, assessed by coronary angiography. This exposure is not assigned by the study investigators and is observed during standard-of-care coronary angiography. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Incidence of atrial coronary artery involvement in patients with newly diagnosed atrial fibrillation during acute STEMI
Aikaikkuna: At the time of coronary angiography
|
Atrial coronary artery involvement is defined as the presence of thrombosis and/or stenosis of atrial coronary artery branches (ROCS, AVNA, RIAA, and LIAA), including assessment of their relationship to the infarct-related artery and TIMI flow, as determined by coronary angiography. |
At the time of coronary angiography
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
All-cause mortality
Aikaikkuna: On discharge from the hospital, an average of 14 days
|
Death from any cause during hospitalization |
On discharge from the hospital, an average of 14 days
|
|
Cardiovascular mortality
Aikaikkuna: On discharge from the hospital, an average of 14 days
|
Death from cardiovascular disease during hospitalization |
On discharge from the hospital, an average of 14 days
|
|
Acute heart failure, Killip class II or higher
Aikaikkuna: On discharge from the hospital, an average of 14 days
|
Development of acute heart failure (Killip stage ≥ II) |
On discharge from the hospital, an average of 14 days
|
|
Thromboembolic complications
Aikaikkuna: On discharge from the hospital, an average of 14 days
|
Development of thromboembolic complications (stroke, pulmonary embolism) |
On discharge from the hospital, an average of 14 days
|
|
Major bleeding, BARC grade 3 or higher
Aikaikkuna: On discharge from the hospital, an average of 14 days
|
Bleeding (BARC score ≥ 3) |
On discharge from the hospital, an average of 14 days
|
Yhteistyökumppanit ja tutkijat
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- SamaraSOKKD_1
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .